BioNTech Shares Fall 4% Despite Positive Outlook For 2022 Vaccine Revenues

Shares of German biotechnology company BioNTech SE (BNTX) are down 4 percent on Tuesday's trading despite the company announcing that it would likely generate up to 17 billion euros or $19 billion in 2022 revenue from the COVID-19 vaccine it co-developed with partner Pfizer Inc. (PFE).

The company expects 13-17 billion euros revenues from the vaccine this year, which compares to the outlook for 16-17 billion euros for 2021.

Currently, at $220.37, the stock has traded between $90.29 and $464.00 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT